EGFR and non-small cell lung carcinoma: In a recent randomized phase II trial (NCT03595644), 62 patients with stage IV EGFR-mutated NSCLC (exon 19 deletion or L858R) who responded to first-line EGFR-TKI therapy and had 1–5 metastatic residual lesions were enrolled.